Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA Antigens | 6 | 2021 | 40 | 2.020 |
Why?
|
| Kidney Transplantation | 24 | 2021 | 490 | 1.810 |
Why?
|
| Tissue Donors | 19 | 2020 | 186 | 1.690 |
Why?
|
| Alleles | 3 | 2021 | 250 | 1.380 |
Why?
|
| Graft Survival | 16 | 2021 | 293 | 0.960 |
Why?
|
| Exons | 2 | 2021 | 52 | 0.830 |
Why?
|
| Genotype | 6 | 2021 | 702 | 0.800 |
Why?
|
| Histocompatibility Testing | 3 | 2020 | 25 | 0.780 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 68 | 0.610 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 13 | 0.590 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 45 | 0.580 |
Why?
|
| Mutation | 1 | 2020 | 497 | 0.530 |
Why?
|
| Pancreas Transplantation | 6 | 2021 | 245 | 0.510 |
Why?
|
| Complement C4 | 1 | 2013 | 4 | 0.400 |
Why?
|
| Apolipoproteins | 5 | 2016 | 194 | 0.400 |
Why?
|
| Gene Dosage | 1 | 2013 | 36 | 0.400 |
Why?
|
| Graft Rejection | 6 | 2018 | 236 | 0.400 |
Why?
|
| Lipoproteins, HDL | 5 | 2016 | 250 | 0.390 |
Why?
|
| Tissue and Organ Procurement | 6 | 2018 | 88 | 0.350 |
Why?
|
| Histocompatibility | 2 | 2020 | 7 | 0.310 |
Why?
|
| Donor Selection | 3 | 2019 | 28 | 0.300 |
Why?
|
| Humans | 32 | 2023 | 32284 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 105 | 0.280 |
Why?
|
| Female | 26 | 2023 | 19947 | 0.260 |
Why?
|
| Male | 25 | 2021 | 19443 | 0.250 |
Why?
|
| Retrospective Studies | 17 | 2021 | 3628 | 0.240 |
Why?
|
| Adult | 24 | 2021 | 9259 | 0.230 |
Why?
|
| Kidney | 5 | 2021 | 521 | 0.220 |
Why?
|
| Middle Aged | 22 | 2021 | 11853 | 0.200 |
Why?
|
| Hemophilia A | 1 | 2023 | 22 | 0.190 |
Why?
|
| African Americans | 5 | 2016 | 1335 | 0.190 |
Why?
|
| Survival Rate | 9 | 2018 | 893 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2015 | 243 | 0.180 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 2240 | 0.180 |
Why?
|
| C-Peptide | 3 | 2021 | 31 | 0.170 |
Why?
|
| Cadaver | 8 | 2018 | 151 | 0.170 |
Why?
|
| Delayed Graft Function | 3 | 2018 | 29 | 0.160 |
Why?
|
| Gene Frequency | 1 | 2020 | 211 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 267 | 0.150 |
Why?
|
| Computational Biology | 1 | 2020 | 99 | 0.150 |
Why?
|
| Codon | 1 | 2019 | 9 | 0.150 |
Why?
|
| Recombination, Genetic | 1 | 2019 | 23 | 0.150 |
Why?
|
| Laboratories | 1 | 2019 | 18 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 132 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2021 | 248 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2019 | 67 | 0.140 |
Why?
|
| Cold Ischemia | 1 | 2018 | 6 | 0.140 |
Why?
|
| Risk Factors | 9 | 2018 | 3934 | 0.140 |
Why?
|
| Patient Selection | 3 | 2014 | 272 | 0.130 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2008 | 35 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 534 | 0.130 |
Why?
|
| Bone Transplantation | 2 | 2008 | 51 | 0.120 |
Why?
|
| Treatment Outcome | 9 | 2016 | 3416 | 0.120 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2016 | 185 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 242 | 0.110 |
Why?
|
| Immunosuppression | 3 | 2011 | 118 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 1050 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2018 | 823 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 302 | 0.100 |
Why?
|
| Immunosuppressive Agents | 3 | 2011 | 248 | 0.100 |
Why?
|
| Age Factors | 5 | 2019 | 1179 | 0.100 |
Why?
|
| Aged | 9 | 2021 | 10265 | 0.090 |
Why?
|
| Young Adult | 5 | 2019 | 2649 | 0.090 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 101 | 0.090 |
Why?
|
| Prognosis | 4 | 2018 | 1534 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 390 | 0.090 |
Why?
|
| Postoperative Period | 3 | 2021 | 95 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 57 | 0.080 |
Why?
|
| Perfusion | 2 | 2008 | 75 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 773 | 0.080 |
Why?
|
| Nephrotic Syndrome | 1 | 2009 | 11 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 16 | 0.080 |
Why?
|
| Adolescent | 6 | 2019 | 3519 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 2009 | 40 | 0.080 |
Why?
|
| Molecular Motor Proteins | 1 | 2009 | 59 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 84 | 0.070 |
Why?
|
| Portal System | 1 | 2008 | 13 | 0.070 |
Why?
|
| Extracorporeal Circulation | 1 | 2008 | 12 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 245 | 0.070 |
Why?
|
| Creatinine | 3 | 2016 | 191 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2007 | 37 | 0.060 |
Why?
|
| Pancreas | 2 | 2021 | 107 | 0.060 |
Why?
|
| Time Factors | 4 | 2016 | 2205 | 0.060 |
Why?
|
| Transplantation Immunology | 1 | 2005 | 30 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2005 | 50 | 0.060 |
Why?
|
| North Carolina | 3 | 2015 | 1300 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2019 | 1233 | 0.050 |
Why?
|
| Hypertension | 1 | 2011 | 979 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 854 | 0.050 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 158 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 622 | 0.050 |
Why?
|
| Factor VIII | 1 | 2023 | 20 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2023 | 15 | 0.050 |
Why?
|
| United States | 3 | 2017 | 4072 | 0.050 |
Why?
|
| Fetus | 1 | 2023 | 76 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 194 | 0.050 |
Why?
|
| Placenta | 1 | 2023 | 74 | 0.050 |
Why?
|
| Haplotypes | 2 | 2015 | 213 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 651 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 60 | 0.040 |
Why?
|
| Nephrectomy | 2 | 2016 | 123 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 287 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 1010 | 0.040 |
Why?
|
| Pregnancy | 1 | 2023 | 961 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2009 | 2316 | 0.030 |
Why?
|
| Child | 2 | 2019 | 2435 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2008 | 34 | 0.030 |
Why?
|
| Death | 2 | 2008 | 51 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 477 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 8199 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2011 | 1840 | 0.030 |
Why?
|
| Alabama | 1 | 2015 | 41 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 30 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 252 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 456 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 294 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 591 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 1076 | 0.020 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2011 | 36 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 305 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3902 | 0.020 |
Why?
|
| Steroids | 1 | 2009 | 35 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 219 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 541 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 140 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 38 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2008 | 66 | 0.020 |
Why?
|
| Drainage | 1 | 2008 | 65 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 43 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2008 | 91 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 194 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 185 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2007 | 52 | 0.020 |
Why?
|
| Body Size | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 236 | 0.020 |
Why?
|
| Nephrons | 1 | 2006 | 10 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 148 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1437 | 0.010 |
Why?
|